Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Nutr.

Sec. Nutritional Epidemiology

Volume 12 - 2025 | doi: 10.3389/fnut.2025.1623295

Dietary Omega-3 Intake May Slow Prostate Cancer Progression and Reduce Mortality Risk: Evidence from Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Provisionally accepted
  • 1The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
  • 2Fujian Medical University, Fuzhou, China

The final, formatted version of the article will be published soon.

Background: Prostate cancer is the second most prevalent malignant cancer globally and the fifth leading cause of cancer-related mortality. Omega-3 PUFAs (including eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA)) may mitigate prostate cancer risk through various molecular mechanisms, such as inhibiting pro-inflammatory eicosanoid production via COX-2 pathway, regulating apoptosis and autophagy, and potentially influencing other signaling pathways like NF-κB. However, existing studies have reported inconsistent findings regarding the effects of Omega-3 fatty acids on prostate cancer, and there is limited large-scale longitudinal data exploring the dose-response relationship. Methods: This study utilized data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial to investigate the associations between Omega-3 (EPA, DPA, DHA) intake from dietary sources and the risk of prostate cancer and mortality. Omega-3 fatty acid intake was assessed via the Dietary History Questionnaire (DHQ). Multivariate Cox proportional hazards regression models, adjusted for key confounders including age, race, BMI, family history, PSA levels, comorbidities, and lifestyle factors, were employed alongside restricted cubic spline (RCS) analysis to account for potential confounding factors. A total of 30,552 male participants aged 55-74 years were included, with a median follow-up time of ≥7 years.The results indicated a linear relationship between Omega-3 fatty acid intake and the overall risk of prostate cancer (HR for highest vs. lowest quintile: 0.90, 95% CI: 0.81-1.00, P=0.053). For prostate cancer mortality, a nonlinear relationship was observed (P nonlinearity=0.009). The risk of death decreased as intake increased below 0.4 g/d , with a hazard ratio of 0.67 (95% CI: 0.49-0.91, P=0.011) for the second quintile compared to the lowest quintile. However, intake exceeding this threshold was associated with an increased risk (HR for highest quintile: 0.70, 95% CI: 0.52-0.95, P=0.021). The RCS analysis revealed a potential U-shaped association for mortality risk, with the lowest risk corresponding to an intake range of approximately 0.15-0.40 g/d. Conclusion: Increased dietary intake of omega-3 fatty acids has been associated with a reduced risk of prostate cancer. However, the association with mortality risk showed a threshold effect, with intakes below 0.4 g/day reducing mortality and higher intakes potentially increasing risk.

Keywords: prostate cancer, omega-3, docosahexaenoic acid, Docosapentaenoic acid, Eeicosapentaenoic acid, Diet, Restricted cubic spline

Received: 05 May 2025; Accepted: 04 Jul 2025.

Copyright: © 2025 Shu, Lin, Yao, Liu, Chen, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Honggeng Wang, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.